Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
- PMID: 34617306
- PMCID: PMC8841129
- DOI: 10.1002/ana.26233
Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
Abstract
Objective: Tau neurofibrillary tangles (T) are the primary driver of downstream neurodegeneration (N) and subsequent cognitive impairment in Alzheimer's disease (AD). However, there is substantial variability in the T-N relationship - manifested in higher or lower atrophy than expected for level of tau in a given brain region. The goal of this study was to determine if region-based quantitation of this variability allows for identification of underlying modulatory factors, including polypathology.
Methods: Cortical thickness (N) and 18 F-Flortaucipir SUVR (T) were computed in 104 gray matter regions from a cohort of cognitively-impaired, amyloid-positive (A+) individuals. Region-specific residuals from a robust linear fit between SUVR and cortical thickness were computed as a surrogate for T-N mismatch. A summary T-N mismatch metric defined using residuals were correlated with demographic and imaging-based modulatory factors, and to partition the cohort into data-driven subgroups.
Results: The summary T-N mismatch metric correlated with underlying factors such as age and burden of white matter hyperintensity lesions. Data-driven subgroups based on clustering of residuals appear to represent different biologically relevant phenotypes, with groups showing distinct spatial patterns of higher or lower atrophy than expected.
Interpretation: These data support the notion that a measure of deviation from a normative relationship between tau burden and neurodegeneration across brain regions in individuals on the AD continuum captures variability due to multiple underlying factors, and can reveal phenotypes, which if validated, may help identify possible contributors to neurodegeneration in addition to tau, which may ultimately be useful for cohort selection in clinical trials. ANN NEUROL 2021;90:751-762.
© 2021 American Neurological Association.
Conflict of interest statement
Figures





References
-
- La Joie R, Visani A, Bourakova V, et al. AV1451-PET cortical uptake and regional distribution predict longitudinal atrophy in Alzheimer’s disease. Alzheimer’s Dement 2017;13.
-
- Schonhaut D, Ossenkoppele R, Schöll M, et al. Associations of [18F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer’s disease. Alzheimer’s Dement 2015;
Publication types
MeSH terms
Substances
Grants and funding
- P30 AG010124/AG/NIA NIH HHS/United States
- R01-AG-056014-04/NH/NIH HHS/United States
- R01-AG-054435-02/NH/NIH HHS/United States
- EB/NIBIB NIH HHS/United States
- R01 NS109260/NS/NINDS NIH HHS/United States
- R01 AG055005/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- R01 AG039474/AG/NIA NIH HHS/United States
- R01 AG054519/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- R01 AG071514/AG/NIA NIH HHS/United States
- R01 AG056014/AG/NIA NIH HHS/United States
- U19 AG024904/AG/NIA NIH HHS/United States
- RF1 AG069474/AG/NIA NIH HHS/United States
- P01 AG066597/AG/NIA NIH HHS/United States